Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia

Blood

Volumn 115, Issue 17, 2010, Pages 3616-3624

  Sasu, Barbra J ^a   Cooke, Keegan S ^a   Arvedson, Tara L ^a   Plewa, Cherylene ^a   Ellison, Aaron R ^a   Sheng, Jackie ^a   Winters, Aaron ^a   Juan, Todd ^a   Li, Hongyan ^a   Begley, C Glenn ^a   Molineux, Graham ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPCIDIN; MESSENGER RNA; MONOCLONAL ANTIBODY AB2.7; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRUCELLA ABORTUS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEATING; INFLAMMATORY ANEMIA; IRON METABOLISM; IRON TRANSPORT; KNOCKIN MOUSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 77951745552     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-245977     Document Type: Article

References (39)

1. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-788. (Pubitemid 36917762)
2. Yuan X-M, Li W. The iron hypothesis of atherosclerosis and its clinical impact. Ann Med. 2003; 35(8):578-591. (Pubitemid 38005315)
3. O'Neil J, Powell L. Clinical aspects of hemochromatosis. Semin Liver Dis. 2005;25(4):381-391.
4. Moos T, Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci. 2004;1012:14-26. (Pubitemid 38453512)
5. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008;10(6):997-1030. (Pubitemid 351451707)
6. Cartwright GE. The anemia of chronic disorders. Semin Hematol. 1966;3(4):351-375.
7. Ganz T. Molecular control of iron transport. J Am Soc Nephrol. 2007;18(2):394-400.
8. Andrews NC. Molecular control of iron metabolism. Best Pract Clin Haematol. 2005;18(2):159-169.
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093. (Pubitemid 40007660)
10. Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 2003;33(1):21-22. (Pubitemid 36068676)
11. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100(10):3776-3781.
12. Lesbordes-Brion J-C, Viatte L, Bennoun M, et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood. 2006;108(4): 1402-1405. (Pubitemid 44232044)
13. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001; 98(15):8780-8785. (Pubitemid 32678104)
14. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A. 2002;99(7):4596-4601. (Pubitemid 34286030)
15. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007;109(9):4038-4044. (Pubitemid 46641759)
16. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-2463. (Pubitemid 36857598)
17. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106(5): 1864-1866. (Pubitemid 41208606)
18. Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood. 113;2009:5277-5286.
19. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant. 2000;15(8):1207-1211. (Pubitemid 30487799)
20. Macdougall IC, Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dialysis Transplant. 2002;17(suppl 1):48-52.
21. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P, Anemia Study G. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer. 2001;37(13):1617-1623. (Pubitemid 32778606)
22. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12): 2485-2489. (Pubitemid 44881220)
23. Pieracci FM, Barie PS. Diagnosis and management of iron-related anemias in critical illness. Crit Care Med. 2006;34(7):1898-1905. (Pubitemid 43982465)
24. Bertero MT, Caligaris-Cappio F. Anemia of chronic disorders in systemic autoimmune diseases. Haematologica. 1997;82(3):375-381. (Pubitemid 28023326)
25. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55(2):648-658. (Pubitemid 29082891)
26. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 35(3):469-476.
27. Horl WH, Jacobs C, Macdougall IC, et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dialysis Transplant. 2000;15(suppl 4):43-50.
28. Bárány P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997;29(4):565-568. (Pubitemid 27155278)
29. Gudbjörnsson B, Hallgren R, Wide L, et al. Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin. Ann Rheum Dis. 1992;51(6):747-752.
30. Nordström D, Lindroth Y, Marsal L, et al. Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatol Int. 1997;17(2):67-73. (Pubitemid 27364011)
31. Li H, Rose MJ, Tran L, et al. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods. 2009;59(3):171-180.
32. Jordan JB, Poppe L, Haniu M, et al. Hepcidin revisited, disulfide connectivity, dynamics, and structure. J Biol Chem. 2009;284(36):24155-24167.
33. Li J, Ram G, Gast K, et al. Detection of intracellular iron by its regulatory effect. Am J Physiol Cell Physiol. 2004;287(6):C1547-C1559. (Pubitemid 39507672)
34. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105(4):1797-1802. (Pubitemid 40223704)
35. Sasu BJ, Hartley C, Schultz H, et al. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. Acta Haematol. 2005;113(3):163-174. (Pubitemid 40663266)
36. Lou D-Q, Nicolas G, Lesbordes J-C, et al. Functional differences between hepcidin 1 and 2 in transgenic mice. Blood. 2004;103(7):2816-2821. (Pubitemid 38393044)
37. Ottenweller JE, Natelson BH, Gause WC, et al. Mouse running activity is lowered by Brucella abortus treatment: a potential model to study chronic fatigue. Physiol Behav. 1998;63(5):795-801.
38. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood. 2005;106(6):2196-2199. (Pubitemid 41291740)
39. Sengoelge G, Sunder-Plassmann G, Horl WH. Potential risk for infection and atherosclerosis due to iron therapy. J Renal Nutr. 2005;15(1):105-110. (Pubitemid 40093692)